Retro Biosciences Brings in $180 Million from People Like Sam Altman
Summary
Sam Altman, Open AI CEO, is one of the investors who recently put $180 million into the new firm Retro Biosciences, which says it will add 10 years to a healthy human lifespan, starting with cellular reprogramming, autophagy, & plasma-inspired therapeuticsRetro Biosciences says the companys mission is to increase a healthy human lifespan by ten years. We are fortunate to have initial funding in the amount of $180 million, which will take us to our first proofs of concept, and secure operation of the company through the decade.In the US, around 90 percent of healthcare spending over $3 trillion goes toward age-related diseases and this trend is echoed throughout the world, explains Retro Biosciences. By focusing on the cellular drivers of aging, Retro will design therapeutics eventually capable of multi-disease prevention.Sam Altman is so high on Retro Biosciences potential that he told MIT Technology Review I basically just took all my liquid net worth and put it into these two companies, I have been an early-stage tech investor in the greatest bull market in history.And Sam Altman also had some encouraging words about the Silicon Valley Bank (SVB) collapse. Today is a good day to offer emergency cash to your startups that need it for payroll or whatever. Its hard for me to imagine depositors actually losing money here, but so stressful in the meantimeOn Friday, Silicon Valley Bank (SVB) collapsed in what was described as the largest failure of a US bank since Washington Mutual in 2008 and the Federal government was forced to take over.